Cytori Therapeutics, Inc. (CYTX) Reports Larger Q3 Loss
Tweet
Share
E-mailGet Alerts CYTX Hot Sheet
Join SI Premium – FREE
Cytori Therapeutics, Inc. (NASDAQ: CYTX) reported Q1 EPS of ($0.23), $0.08 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.36 million versus the consensus estimate of $3.21 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Jabil (JBL) Tops Q4 EPS by 34c, Beats on Revenue; Offers FY Guidance
- IDT Corp. (IDT) Misses Q4 EPS by 3c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
